GVK Biosciences Joins ResearchPoint Global
Addition of India-based CRO expands reach of worldwide clinical organization
As the growth of India’s participation in global clinical programs continues to increase at a rapid pace, RPG strategically sought to expand its reach to this region. According to The Goldman Sachs Group, Inc., “India presents an attractive region for clinical trials given a population of over one billion, a large number of English-speaking patients, and a well developed information technology industry.” 1
RPG’s expansion into India offers numerous advantages for running clinical trials: a large population, qualified medical personnel, and well-established regulations. GVK BIO complements RPG’s current presence in the Americas, Europe (Western, Central, and Eastern) and Africa.
“RPG is strategically expanding our global footprint with qualified, like-minded CROs who have extensive drug development experience across a broad range of therapeutic areas,” said Matt Walker, Executive Vice President of Marketing and Business Development with ResearchPoint, a member of RPG. “GVK Biosciences has built an exceptional reputation as a full-service clinical service provider in India and we look forward to leveraging their deep local knowledge for the benefit of our clients.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.